Cipla Limited — Updates, 25-07-2025: Press Release

Cipla reported its financial results for the quarter, showing revenue at INR 6,957 Cr, up 4% YoY, and PAT rising 10% to INR 1,298 Cr. EBITDA margin stood at 25.6%. The One-India business recorded its first-ever INR 3,000 Cr opening quarter, growing 6%. North America revenue was INR 1,933 Cr, driven by new asset launches like Nano Paclitaxel and Nilotinib Capsules. Cipla also entered a strategic agreement for its first U.S. biosimilar, expected Q2 FY26. One Africa and Emerging Markets posted healthy growth. The company maintains a strong net cash of INR 10,379 Cr.